This article needs more reliable medical references for verification or relies too heavily on primary sources. (January 2021) |
Clinical data | |
---|---|
Trade names | Noopept |
Other names | omberacetam; GVS-111; DVD-111; SGS-111; benzylcarbonyl-Pro-Gly-OEt |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H22N2O4 |
Molar mass | 318.373 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cyclic glycine-proline.[a][2] Other names include the brand name Noopept (Russian: Ноопепт), developmental code GVS-111, and proposed INN omberacetam.[2][3][4]
Its synthesis was first reported in 1996.[2] It is orally available. As of 2017, its metabolism and elimination half-life in humans were not well understood.[2]
It has been evaluated for neuroprotective effects in treating brain injuries and stroke.[5]
Alternative Names: DVD-111; GVS 111; Noopept
Cite error: There are <ref group=lower-alpha>
tags or {{efn}}
templates on this page, but the references will not show without a {{reflist|group=lower-alpha}}
template or {{notelist}}
template (see the help page).